『徳島大学 教育・研究者情報データベース (EDB)』---[学外] /
ID: Pass:

登録内容 (EID=369262)

EID=369262EID:369262, Map:0, LastModified:2020年9月11日(金) 15:28:17, Operator:[大家 隆弘], Avail:TRUE, Censor:0, Owner:[宇都 義浩], Read:継承, Write:継承, Delete:継承.
種別 (必須): 学術論文 (審査論文) [継承]
言語 (必須): 英語 [継承]
招待 (推奨):
審査 (推奨): Peer Review [継承]
カテゴリ (推奨): 研究 [継承]
共著種別 (推奨): 国内共著 (徳島大学内研究者と国内(学外)研究者との共同研究 (国外研究者を含まない)) [継承]
学究種別 (推奨): 博士後期課程学生による研究報告 [継承]
組織 (推奨): 1.徳島大学.大学院社会産業理工学研究部.生物資源産業学域 (2017年4月1日〜) [継承]
著者 (必須): 1. (英) Sootome Hiroshi (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
2. (英) Miura Akihiro (日) 三浦 晃敬 (読) みうら あきひろ
役割 (任意):
貢献度 (任意):
学籍番号 (推奨): **** [ユーザ]
[継承]
3. (英) Masuko Norio (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
4. (英) Suzuki Takamasa (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
5.宇都 義浩 ([徳島大学.大学院社会産業理工学研究部.生物資源産業学域.応用生命系.応用生物資源学分野]/[徳島大学.生物資源産業学部.生物資源産業学科.応用生命講座])
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
6. (英) Hirai Hiroshi (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
題名 (必須): (英) Aurora A inhibitor TAS-119 enhances antitumor efficacy of taxanes in vitro and in vivo: preclinical studies as guidance for clinical development and trial design  (日)    [継承]
副題 (任意):
要約 (任意): (英) TAS-119 is a novel orally active, selective inhibitor of Aurora kinase A identified as a clinical candidate for efficacy testing in combination with taxanes. In vitro, TAS-119 enhanced cell growth inhibition of paclitaxel in multiple human cancer cell lines derived from various tissues, including paclitaxel-resistant cell lines. Interestingly, TAS-119 did not enhance paclitaxel antitumor activity in normal lung diploid fibroblast cell lines WI-38 and MRC5. In vivo, TAS-119 enhanced the antitumor efficacy of paclitaxel and docetaxel in multiple models at doses inhibitory to Aurora A in tumors. Moreover, the drug combination was well tolerated, and TAS-119 did not exaggerate clinically documented side effects of taxanes, neutropenia and neurotoxicity, in rats. The same TAS-119 concentration enhanced the cell growth inhibitory activity of three clinically approved taxanes, paclitaxel, docetaxel, and cabazitaxel. The degree of enhancement calculated as fold of change of the IC50 value for each taxane was almost the same among the three taxanes. We conducted in vitro and in vivo experiments to develop an optimized combination therapy regimen for TAS-119 with paclitaxel/docetaxel. Using in vitro and in vivo models, we tested the drug administration order for TAS-119 combined with paclitaxel and the TAS-119 treatment duration. The best regimen in preclinical models was combining paclitaxel or docetaxel treatment with 4 days of TAS-119 dosing, which was initiated on the same day as the paclitaxel or docetaxel administration or one day later. This information provided guidance for the design of a clinical trial of TAS-119 and paclitaxel or docetaxel combination.  (日)    [継承]
キーワード (推奨):
発行所 (推奨): American Association for Cancer Research [継承]
誌名 (必須): Molecular Cancer Therapeutics ([American Association for Cancer Research])
(pISSN: 1535-7163, eISSN: 1538-8514)

ISSN (任意): 1538-8514
ISSN: 1535-7163 (pISSN: 1535-7163, eISSN: 1538-8514)
Title: Molecular cancer therapeutics
Title(ISO): Mol Cancer Ther
Publisher: American Association for Cancer Research
 (NLM Catalog  (Scopus  (CrossRef (Scopus information is found. [need login])
[継承]
[継承]
(必須): [継承]
(必須): [継承]
(必須): [継承]
都市 (任意):
年月日 (必須): 西暦 2020年 8月 11日 (令和 2年 8月 11日) [継承]
URL (任意):
DOI (任意): 10.1158/1535-7163.MCT-20-0036    (→Scopusで検索) [継承]
PMID (任意): 32788206    (→Scopusで検索) [継承]
NAID (任意):
WOS (任意):
Scopus (任意):
評価値 (任意):
被引用数 (任意):
指導教員 (推奨): 1.宇都 義浩 ([徳島大学.大学院社会産業理工学研究部.生物資源産業学域.応用生命系.応用生物資源学分野]/[徳島大学.生物資源産業学部.生物資源産業学科.応用生命講座]) [継承]
備考 (任意): 1.(英) Article.ELocationID: molcanther.0036.2020  (日)    [継承]
2.(英) Article.ELocationID: 10.1158/1535-7163.MCT-20-0036  (日)    [継承]
3.(英) Article.PublicationTypeList.PublicationType: Journal Article  (日)    [継承]

標準的な表示

和文冊子 ● Hiroshi Sootome, Akihiro Miura, Norio Masuko, Takamasa Suzuki, Yoshihiro Uto and Hiroshi Hirai : Aurora A inhibitor TAS-119 enhances antitumor efficacy of taxanes in vitro and in vivo: preclinical studies as guidance for clinical development and trial design, Molecular Cancer Therapeutics, 2020.
欧文冊子 ● Hiroshi Sootome, Akihiro Miura, Norio Masuko, Takamasa Suzuki, Yoshihiro Uto and Hiroshi Hirai : Aurora A inhibitor TAS-119 enhances antitumor efficacy of taxanes in vitro and in vivo: preclinical studies as guidance for clinical development and trial design, Molecular Cancer Therapeutics, 2020.

関連情報

Number of session users = 6, LA = 0.40, Max(EID) = 382747, Max(EOID) = 1022227.